Cell-penetrating peptides as nucleic acid delivery systems: From biophysics to biological applications

Current Pharmaceutical Design

Volumn 19, Issue 16, 2013, Pages 2895-2923

  Trabulo, Sara ^a,c   Cardoso, Ana L ^a   Cardoso, Ana M S ^a   Morais, Catarina M ^a   Jurado, Amália S ^a,b   Pedroso de Lima, Maria C ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Cell internalization mechanisms; Cell penetrating peptides; CPP chemical modifications; CPP membrane lipid interactions; Endosomal escape; Nucleic acid delivery

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTENNAPEDIA PROTEIN; ARGININE; CELL PENETRATING PEPTIDE; CHIMERIC PROTEIN; CITRULLINE; DERMASEPTIN; DODECYL SULFATE SODIUM; DOXORUBICIN; HISTIDINE; LIPOFECTAMINE; LYSINE; MASTOPARAN; NANOCARRIER; NUCLEIC ACID; ORNITHINE; PENETRATIN; PEPTIDE NUCLEIC ACID; PLASMID DNA; POLYGLACTIN; PROTEOGLYCAN; SMALL INTERFERING RNA;

AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; BETA SHEET; BIOAVAILABILITY; CELL MEMBRANE; CELL SURFACE; CELL VIABILITY; CELLULAR DISTRIBUTION; CHEMICAL MODIFICATION; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CYTOLOGY; CYTOPLASM; CYTOTOXICITY; DNA BINDING; DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; GENE SILENCING; GENE TARGETING; GENE TRANSFER; GENE VECTOR; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; INTERNALIZATION; INTRACELLULAR SPACE; MEMBRANE MODEL; MEMBRANE VESICLE; MICELLE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PHOSPHOLIPID BILAYER; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; REVIEW; SIMIAN VIRUS 40; STATIC ELECTRICITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL TRANSPORT; CELL MEMBRANE; CELL-PENETRATING PEPTIDES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; NUCLEIC ACIDS;

EID: 84878655380     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319160006     Document Type: Review

References (161)

1. Merril CR, Geier MR, Petricciani JC. Bacterial virus gene expression in human cells. Nature 1971; 233: 398-400.
2. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-93.
3. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 1991; 88: 1864-8.
4. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285: 1569-72.
5. Pooga M, Hällbrink M, Zorko M, Langel Ü. Cell penetration by transportan. FASEB J 1998; 12: 67-77.
6. Zhang C, Tang N, Liu X, Liang W, Xu W, Torchilin VP. siRNAcontaining liposomes modified with polyarginine effectively silence the targeted gene. J Control Release 2006; 112: 229-39.
7. Nguyen QN, Chavli RV, Marques JT, et al. Light controllable siRNAs regulate gene suppression and phenotypes in cells. Biochim Biophys Acta 2006; 1758: 394-403.
8. Garnon J, Lachance C, Di Marco S, et al. Fragile X-related protein FXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the post-transcriptional level. J Biol Chem 2005; 280: 5750-63.
9. Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today 2012.
10. Koppelhus U, Awasthi SK, Zachar V, Holst HU, Ebbesen P, Nielsen PE. Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense Nucleic Acid Drug Dev 2002; 12: 51-63.
11. Abes S, Moulton HM, Clair P, et al. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 2006; 116: 304-13.
12. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19: 1173-6.
13. Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003; 31: 2717-24.
14. Meade BR, Dowdy SF. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Delivery Rev 2008; 60: 530-6.
15. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009; 157: 195-206.
16. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 1997; 25: 2730-6.
17. Richard JP, Melikov K, Vives E, et al. Cell-penetrating peptides. J Biol Chem 2003; 278: 585-90.
18. Vivès E, Richard JP, Rispal C, Lebleu B. TAT peptide internalization: seeking the mechanism of entry. Curr Protein Pept Sci. 2003; 4: 125-32.
19. Eiriksdottir E, Konate K, Langel U, Divita G, Deshayes S. Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochim Biophys Acta 2010; 1798: 1119-28.
20. Kamide K, Nakakubo H, Uno S, Fukamizu A. Isolation of novel cell-penetrating peptides from a random peptide library using in vitro virus and their modifications. Int J Mol Med 2010; 25: 41-51.
21. Marks JR, Placone J, Hristova K, Wimley WC. Spontaneous membrane-translocating peptides by orthogonal high-throughput screening. J Am Chem Soc 2011; 133: 8995-9004.
22. Ziegler A, Seelig J. High affinity of the cell-penetrating peptide HIV-1 Tat-PTD for DNA. Biochemistry 2007; 46: 8138-45.
23. Mann A, Thakur G, Shukla V, et al. Differences in DNA condensation and release by lysine and arginine homopeptides govern their DNA delivery efficiencies. Mol Pharm 2011; 8: 1729-41.
24. Gautam A, Singh H, Tyagi A, et al. CPPsite: a curated database of cell penetrating peptides. Database (Oxford) 2012; 2012: bas015.
25. Sanders WS, Johnston CI, Bridges SM, Burgess SC, Willeford KO. Prediction of cell penetrating peptides by support vector machines. PLoS Comput Biol 2011; 7: e1002101.
26. Gehring WJ, Affolter M, Burglin T. Homeodomain proteins. Annu Rev Biochem 1994; 63: 487-526.
27. Gehring WJ, Qian YQ, Billeter M, et al. Homeodomain-DNA recognition. Cell 1994; 78: 211-23.
28. Le Roux I, Joliot AH, Bloch-Gallego E, Prochiantz A, Volovitch M. Neurotrophic activity of the Antennapedia homeodomain depends on its specific DNA-binding properties. Proc Natl Acad Sci USA 1993; 90: 9120-4.
29. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269: 10444-50.
30. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996; 271: 18188-93.
31. Binder H, Lindblom G. Charge-dependent translocation of the Trojan peptide penetratin across lipid membranes. Biophys J 2003; 85: 982-95.
32. Christiaens B, Grooten J, Reusens M, et al. Membrane interaction and cellular internalization of penetratin peptides. Eur J Biochem 2004; 271: 1187-97.
33. Christiaens B, Symoens S, Vanderheyden S, et al. Tryptophan fluorescence study of the interaction of penetratin peptides with model membranes. Eur J Biochem 2002; 269: 2918-26.
34. Jiao CY, Delaroche D, Burlina F, Alves ID, Chassaing G, Sagan S. Translocation and endocytosis for cell-penetrating peptide internalization. J Biol Chem 2009; 284: 33957-65.
35. Lamazière A, Wolf C, Lambert O, Chassaing G, Trugnan G, Ayala-Sanmartin J. The homeodomain derived peptide penetratin induces curvature of fluid membrane domains. PLoS ONE 2008; 3: e1938.
36. Lamaziere A, Maniti O, Wolf C, et al. Lipid domain separation, bilayer thickening and pearling induced by the cell penetrating peptide penetratin. Biochim Biophys Acta 2010; 1798: 2223-30.
37. Alves ID, Jiao C-Y, Aubry S, et al. Cell biology meets biophysics to unveil the different mechanisms of penetratin internalization in cells. Biochim Biophys Acta 2010; 1798: 2231-9.
38. Caesar CEB, Esbjörner EK, Lincoln P, Nordén B. Membrane interactions of cell-penetrating peptides probed by tryptophan fluorescence and dichroism techniques: correlations of structure to cellular uptake. Biochemistry 2006; 45: 7682-92.
39. Thorén PEG, Persson D, Karlsson M, Nordén B. The Antennapedia peptide penetratin translocates across lipid bilayers-the first direct observation. FEBS Lett 2000; 482: 265-8.
40. Drin G, Mazel M, Clair P, Mathieu D, Kaczorek M, Temsamani J. Physico-chemical requirements for cellular uptake of pAntp peptide. Eur J Biochem 2001; 268: 1304-14.
41. Magzoub M, Eriksson LEG, Gräslund A. Conformational states of the cell-penetrating peptide penetratin when interacting with phospholipid vesicles: effects of surface charge and peptide concentration. Biochim Biophys Acta 2002; 1563: 53-63.
42. Persson D, Thorén PEG, Lincoln P, Nordén B. Vesicle membrane interactions of penetratin analogues. Biochemistry 2004; 43: 11045-55.
43. Thorén PEG, Persson D, Isakson P, Goksör M, Önfelt A, Nordén B. Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells. Biochem Biophys Res Commun 2003; 307: 100-7.
44. Åmand HL, Boström CL, Lincoln P, Nordén B, Esbjörner EK. Binding of cell-penetrating penetratin peptides to plasma membrane vesicles correlates directly with cellular uptake. Biochim Biophys Acta 2011; 1808: 1860-7.
45. Lundberg P, El-Andaloussi S, Sütlü T, Johansson H, Langel Ü. Delivery of short interfering RNA using endosomolytic cellpenetrating peptides. FASEB J 2007; 21: 2664-71.
46. Åmand HL, Nordén B, Fant K. Functionalization with C-terminal cysteine enhances transfection efficiency of cell-penetrating peptides through dimer formation. Biochem Biophys Res Commun 2012; 418: 469-74.
47. Langel Ü, Pooga M, Kairane C, Zilmer M, Bartfai T. A galaninmastoparan chimeric peptide activates the Na+, K+-ATPase and reverses its inhibition by ouabain. Regul Pept 1996; 62: 47-52.
48. Pooga M., Juréus A., Razaei K., et al. Novel galanin receptor ligands. J Pept Res 1998; 51: 65-74.
49. Lindberg M, Jarvet J, Langel Ü, Gräslund A. Secondary structure and position of the cell-penetrating peptide transportan in SDS micelles as determined by NMR. Biochemistry 2001; 40: 3141-9.
50. Magzoub M, Kilk K, Eriksson LEG, Langel Ü, Gräslund A. Interaction and structure induction of cell-penetrating peptides in the presence of phospholipid vesicles. Biochim Biophys Acta 2001; 1512: 77-89.
51. Magzoub M, Eriksson LEG, Gräslund A. Comparison of the interaction, positioning, structure induction and membrane perturbation of cell-penetrating peptides and non-translocating variants with phospholipid vesicles. Biophys Chem 2003; 103: 271-88.
52. Bárány-Wallje E, Andersson A, Gräslund A, Mäler L. NMR solution structure and position of transportan in neutral phospholipid bicelles. FEBS Lett 2004; 567: 265-9.
53. Lindberg M, Biverståhl H, Gräslund A, Mäler L. Structure and positioning comparison of two variants of penetratin in two different membrane mimicking systems by NMR. Eur J Biochem 2003; 270: 3055-63.
54. Soomets U, Lindgren M, Gallet X, et al. Deletion analogues of transportan. Biochim Biophys Acta 2000; 1467: 165-76.
55. Song J, Kai M, Zhang W, et al. Cellular uptake of transportan 10 and its analogs in live cells: selectivity and structure-activity relationship studies. Peptides 2011; 32: 1934-41.
56. Yandek LE, Pokorny A, Florén A, Knoelke K, Langel Ü, Almeida PFF. Mechanism of the cell-penetrating peptide transportan 10 permeation of lipid bilayers. Biophys J 2007; 92: 2434-44.
57. Mäe M, El Andaloussi S, Lundin P, et al. A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J Control Release 2009; 134: 221-7.
58. Ezzat K, EL Andaloussi S, Zaghloul EM, et al. PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res 2011; 39: 5284-98.
59. EL Andaloussi S, Lehto T, Mäger I, et al. Design of a peptidebased vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res 2011; 39: 3972-87.
60. Anko M, Majhenc J, Kogej K, et al. Influence of stearyl and trifluoromethylquinoline modifications of the cell penetrating peptide TP10 on its interaction with a lipid membrane. Biochim Biophys Acta 2012; 1818: 915-24.
61. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell 1988; 55: 1179-88.
62. Vivès E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272: 16010-7.
63. Mitchell DJ, Steinman L, Kim DT, Fathman CG, Rothbard JB. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 2000; 56: 318-25.
64. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA 2000; 97: 13003-8.
65. Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich Peptides. J Biol Chem 2001; 276: 5836-40.
66. Futaki S, Ohashi W, Suzuki T, et al. Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem 2001; 12: 1005-11.
67. Khalil IA, Futaki S, Niwa M, et al. Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation. Gene Ther 2004; 11: 636-44.
68. Katayama S, Hirose H, Takayama K, Nakase I, Futaki S. Acylation of octaarginine: Implication to the use of intracellular delivery vectors. J Control Release 2011; 149: 29-35.
69. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2002; 277: 2437-43.
70. Terrone D, Sang SLW, Roudaia L, Silvius JR. Penetratin and related cell-penetrating cationic peptides can translocate across lipid bilayers in the presence of a transbilayer potential. Biochemistry 2003; 42: 13787-99.
71. Nakase I, Niwa M, Takeuchi T, et al. Cellular uptake of argininerich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 2004; 10: 1011-22.
72. Nakase I, Tadokoro A, Kawabata N, et al. Interaction of argininerich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry 2007; 46: 492-501.
73. Lamazière A, Burlina F, Wolf C, Chassaing G, Trugnan G, Ayala-Sanmartin J. Non-metabolic membrane tubulation and permeability induced by bioactive peptides. PLoS ONE 2007; 2: e201.
74. Fretz MM, Penning NA, Al-Taei S, et al. Temperature-, concentration-and cholesterol-dependent translocation of L-and D-octaarginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem J. 2007; 403: 335-42.
75. Walrant A, Correia I, Jiao C-Y, et al. Different membrane behaviour and cellular uptake of three basic arginine-rich peptides. Biochim Biophys Acta 2011; 1808: 382-93.
76. Takayama K, Nakase I, Michiue H, et al. Enhanced intracellular delivery using arginine-rich peptides by the addition of penetration accelerating sequences (Pas). J Control Release 2009; 138: 128-33.
77. Takayama K, Hirose H, Tanaka G, et al. Effect of the attachment of a penetration accelerating sequence and the influence of hydrophobicity on octaarginine-mediated intracellular delivery. Mol Pharm 2012; 9: 1222-30.
78. Deshayes S, Plénat T, Aldrian-Herrada G, Divita G, Le Grimellec C, Heitz F. Primary amphipathic cell-penetrating peptides: structural requirements and interactions with model membranes. Biochemistry 2004; 43: 7698-706.
79. Weller K, Lauber S, Lerch M, Renaud A, Merkle HP, Zerbe O. Biophysical and biological studies of end-group-modified derivatives of Pep-1. Biochemistry 2005; 44: 15799-811.
80. Deshayes S, Gerbal-Chaloin S, Morris MC, et al. On the mechanism of non-endosomial peptide-mediated cellular delivery of nucleic acids. Biochim Biophys Acta 2004; 1667: 141-7.
81. Deshayes S, Morris MC, Divita G, Heitz F. Interactions of amphipathic carrier peptides with membrane components in relation with their ability to deliver therapeutics. J Pept Sci 2006; 12: 758-65.
82. Henriques ST, Costa J, Castanho MARB. Re-evaluating the role of strongly charged sequences in amphipathic cell-penetrating peptides: a fluorescence study using Pep-1. FEBS Lett 2005; 579: 4498-502.
83. Bobone S, Piazzon A, Orioni B, et al. The thin line between cellpenetrating and antimicrobial peptides: the case of Pep-1 and Pep-1-K. J Pept Sci 2011; 17: 335-41.
84. Hariton-Gazal E, Feder R, Mor A, et al. Targeting of nonkaryophilic cell-permeable peptides into the nuclei of intact cells by covalently attached nuclear localization signals. Biochemistry 2002; 41: 9208-14.
85. Mano M, Teodósio C, Paiva A., Simões S, Pedroso de Lima MC. On the mechanisms of the internalization of S4(13)-PV cellpenetrating peptide. Biochem J. 2005; 390: 603-12.
86. Gerbal-Chaloin S, Gondeau C, Aldrian-Herrada G, Heitz F, Gauthier-Rouvière C, Divita G. First step of the cell-penetrating peptide mechanism involves Rac1 GTPase-dependent actin-network remodelling. Biol Cell 2007; 99: 223-38.
87. Mano M, Henriques A, Paiva A, et al. Cellular uptake of S413-PV peptide occurs upon conformational changes induced by peptide-membrane interactions. Biochim Biophys Acta 2006; 1758: 336-46.
88. Mano M, Henriques A, Paiva A, et al. Interaction of S413-PV cell penetrating peptide with model membranes: relevance to peptide translocation across biological membranes. J Pept Sci 2007; 13: 301-13.
89. Padari Kr, Koppel K, Lorents A, et al. S413-PV Cell-penetrating peptide forms nanoparticle-like structures to gain entry into cells. Bioconjug Chem 2010; 21: 774-83.
90. Muñoz-Morris MA, Heitz F, Divita G, Morris MC. The peptide carrier Pep-1 forms biologically efficient nanoparticle complexes. Biochem Biophys Res Commun 2007; 355: 877-82.
91. Crombez L, Morris MC, Deshayes S, Heitz F, Divita G. Peptidebased nanoparticle for ex vivo and in vivo dug delivery. Curr Pharm Des 2008; 14: 3656-65.
92. Cardoso AMS, Trabulo S, Cardoso AL, et al. S4(13)-PV cellpenetrating peptide induces physical and morphological changes in membrane-mimetic lipid systems and cell membranes: Implications for cell internalization. Biochim Biophys Acta 2012; 1818: 877-88.
93. Trabulo S, Mano M, Faneca H, et al. S413-PV cell penetrating peptide and cationic liposomes act synergistically to mediate intracellular delivery of plasmid DNA. J Gene Med 2008; 10: 1210-22.
94. Trabulo S, Resina S, Simões S, Lebleu B, Pedroso de Lima MC. A non-covalent strategy combining cationic lipids and CPPs to enhance the delivery of splice correcting oligonucleotides. J Control Release 2010; 145: 149-58.
95. Morris MC, Chaloin L, Choob M, Archdeacon J, Heitz F, Divita G. Combination of a new generation of PNAs with a peptide-based carrier enables efficient targeting of cell cycle progression. Gene Ther 2004; 11: 757-64.
96. Morris MC, Gros E, Aldrian-Herrada G, et al. A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res 2007; 35: e49.
97. Pooga M, Soomets U, Hallbrink M, et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 1998; 16: 857-61.
98. Moulton HM, Hase MC, Smith KM, Iversen PL. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev 2003; 13: 31-43.
99. El-Andaloussi S, Johansson HJ, Lundberg P, Langel U. Induction of splice correction by cell-penetrating peptide nucleic acids. J Gene Med 2006; 8: 1262-73.
100. Abes S, Moulton H, Turner J, et al. Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splicecorrecting oligonucleotides. Biochem Soc Trans 2007; 35: 53-5.
101. Bendifallah N, Rasmussen FW, Zachar V, Ebbesen P, Nielsen PE, Koppelhus U. Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA). Bioconjug Chem 2006; 17: 750-8.
102. Abes S, Turner JJ, Ivanova GD, et al. Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res 2007; 35: 4495-502.
103. Cheng CJ, Saltzman WM. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cellpenetrating peptides. Biomaterials 2011; 32: 6194-203.
104. Cheng CJ, Saltzman WM. Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol Pharm 2012; 9: 1481-8.
105. Kilk K, El-Andaloussi S, Jarver P, et al. Evaluation of transportan 10 in PEI mediated plasmid delivery assay. J Control Release 2005; 103: 511-23.
106. Kang SH, Cho MJ, Kole R. Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 1998; 37: 6235-9.
107. Lehto T, Abes R, Oskolkov N, et al. Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. J Control Release 2010; 141: 42-51.
108. Lehto T, Simonson OE, Mager I, et al. A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol Ther 2011; 19: 1457-67.
109. Hassane FS, Abes R, El Andaloussi S, et al. Insights into the cellular trafficking of splice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides. J Control Release 2011; 153: 163-72.
110. Oskolkov N, Arukuusk P, Copolovici DM, et al. NickFects, phosphorylated derivatives of transportan 10 for cellular delivery of oligonucleotides. Int J Peptide Res Therapeut 2011; 17: 147-57.
111. Astriab-Fisher A, Sergueev DS, Fisher M, Shaw BR, Juliano RL. Antisense inhibition of P-glycoprotein expression using peptideoligonucleotide conjugates. Biochem Pharmacol 2000; 60: 83-90.
112. Chiu YL, Ali A, Chu CY, Cao H, Rana TM. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004; 11: 1165-75.
113. Wang X, Huq I, Rana TM. HIV-1 TAR RNA Recognition by an unnatural biopolymer. J Am Chem Soc 1997; 119: 6444-5.
114. Moschos SA, Jones SW, Perry MM, et al. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 2007; 18: 1450-9.
115. Meng S, Wei B, Xu R, et al. TAT peptides mediated small interfering RNA delivery to Huh-7 cells and efficiently inhibited hepatitis C virus RNA replication. Intervirology 2009; 52: 135-40.
116. Ignatovich IA, Dizhe EB, Pavlotskaya AV, et al. Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. J Biol Chem 2003; 278: 42625-36.
117. Tung CH, Mueller S, Weissleder R. Novel branching membrane translocational peptide as gene delivery vector. Bioorg Med Chem 2002; 10: 3609-14.
118. Sandgren S, Cheng F, Belting M. Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. Role for cellsurface proteoglycans. J Biol Chem 2002; 277: 38877-83.
119. Siprashvili Z, Scholl FA, Oliver SF, et al. Gene transfer via reversible plasmid condensation with cysteine-flanked, internally spaced arginine-rich peptides. Hum Gene Ther 2003; 14: 1225-33.
120. Lo SL, Wang S. An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. Biomaterials 2008; 29: 2408-14.
121. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 2001; 98: 8786-91.
122. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos-Sternberg B, D'Souza GG. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA 2003; 100: 1972-7.
123. Rudolph C, Plank C, Lausier J, Schillinger U, Muller RH, Rosenecker J. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem 2003; 278: 11411-8.
124. Hyndman L, Lemoine JL, Huang L, Porteous DJ, Boyd AC, Nan X. HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J Control Release 2004; 99: 435-44.
125. Kleemann E, Neu M, Jekel N, et al. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release 2005; 109: 299-316.
126. Vandenbroucke RE, De Smedt SC, Demeester J, Sanders NN. Cellular entry pathway and gene transfer capacity of TAT-modified lipoplexes. Biochim Biophys Acta 2007; 1768: 571-9.
127. Zuhorn IS, Kalicharan R, Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J Biol Chem 2002; 277: 18021-8.
128. MacKay JA, Li W, Huang Z, et al. HIV TAT peptide modifies the distribution of DNA nanolipoparticles following convectionenhanced delivery. Mol Ther 2008; 16: 893-900.
129. Song HP, Yang JY, Lo SL, et al. Gene transfer using selfassembled ternary complexes of cationic magnetic nanoparticles, plasmid DNA and cell-penetrating Tat peptide. Biomaterials 2012; 31: 769-78.
130. Nam HY, Kim J, Kim S, Yockman JW, Kim SW, Bull DA. Cell penetrating peptide conjugated bioreducible polymer for siRNA delivery. Biomaterials 2011; 32: 5213-22.
131. Xiong XB, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 2011; 5: 5202-13.
132. Eguchi A, Meade BR, Chang YC, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 2009; 27: 567-71.
133. Arthanari Y, Pluen A, Rajendran R, Aojula H, Demonacos C. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells. J Control Release 2010; 145: 272-80.
134. Uchida T, Kanazawa T, Takashima Y, Okada H. Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002. Chem Pharm Bull (Tokyo) 2011; 59: 196-201.
135. Govindarajan S, Sivakumar J, Garimidi P, et al. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptideaffibody bioconjugate. Biomaterials 2012; 33: 2570-82.
136. Liu K, Wang X, Fan W, et al. Degradable polyethylenimine derivate coupled to a bifunctional peptide R13 as a new gene-delivery vector. Int J Nanomedicine 2012; 7: 1149-62.
137. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol 2000; 10: 290-5.
138. Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 2004; 15: 290-9.
139. Tonges L, Lingor P, Egle R, Dietz GP, Fahr A, Bahr M. Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons. RNA 2006; 12: 1431-8.
140. Kim WJ, Christensen LV, Jo S, et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther 2006; 14: 343-50.
141. Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007; 448: 39-43.
142. Gong C, Li X, Xu L, Zhang YH. Target delivery of a gene into the brain using the RVG29-oligoarginine peptide. Biomaterials 2012; 33: 3456-63.
143. Said Hassane F, Saleh AF, Abes R, Gait MJ, Lebleu B. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci 2010; 67: 715-26.
144. Jearawiriyapaisarn N, Moulton HM, Buckley B, et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 2008; 16: 1624-9.
145. Yin H, Moulton HM, Betts C, et al. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 2009; 18: 4405-14.
146. Yin H, Moulton HM, Seow Y, et al. Cell-penetrating peptideconjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 2008; 17: 3909-18.
147. Kogure K, Moriguchi R, Sasaki K, Ueno M, Futaki S, Harashima H. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J Control Release 2004; 98: 317-23.
148. Khalil IA, Kogure K, Futaki S, et al. Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. Gene Ther 2007; 14: 682-9.
149. Khalil IA, Kogure K, Futaki S, Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 2006; 281: 3544-51.
150. El-Sayed A, Khalil IA, Kogure K, Futaki S, Harashima H. Octaarginine-and octalysine-modified nanoparticles have different modes of endosomal escape. J Biol Chem 2008; 283: 23450-61.
151. Nakamura Y, Kogure K, Futaki S, Harashima H. Octaargininemodified multifunctional envelope-type nano device for siRNA. J Control Release 2007; 119: 360-7.
152. Hayashi Y, Yamauchi J, Khalil IA, Kajimoto K, Akita H, Harashima H. Cell penetrating peptide-mediated systemic siRNA delivery to the liver. Int J Pharm 2011; 419: 308-13.
153. Mudhakir D, Akita H, Khalil IA, Futaki S, Harashima H. Pharmacokinetic analysis of the tissue distribution of octaarginine modified liposomes in mice. Drug Metab Pharmacokinet 2005; 20: 275-81.
154. Saw PE, Ko YT, Jon S. Efficient liposomal nanocarrier-mediated oligodeoxynucleotide delivery involving dual use of a cellpenetrating peptide as a packaging and intracellular delivery agent. Macromol Rapid Commun 2011; 31: 1155-62.
155. Choi YS, Lee JY, Suh JS, et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 2010; 31: 1429-43.
156. Morris MC, Chaloin L, Mery J, Heitz F, Divita G. A novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res 1999; 27: 3510-7.
157. Zeineddine D, Papadimou E, Chebli K, et al. Oct-3/4 dose dependently regulates specification of embryonic stem cells toward a cardiac lineage and early heart development. Dev Cell 2006; 11: 535-46.
158. Veldhoen S, Laufer SD, Trampe A, Restle T. Cellular delivery of small interfering RNA by a non-covalently attached cellpenetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res 2006; 34: 6561-73.
159. Laufer SD, Recke AL, Veldhoen S, Trampe A, Restle T. Noncovalent peptide-mediated delivery of chemically modified steric block oligonucleotides promotes splice correction: quantitative analysis of uptake and biological effect. Oligonucleotides 2009; 19: 63-80.
160. Li S, Huang L. Lipidic supramolecular assemblies for gene transfer. J Liposome Res 1996; 6: 589-608.
161. Simoes S, Slepushkin V, Pires P, Gaspar R, de Lima MP, Duzgunes N. Mechanisms of gene transfer mediated by lipoplexes associated with targeting ligands or pH-sensitive peptides. Gene Ther 1999; 6: 1798-807.